Financial Data and Key Metrics Changes - The company has used approximately $5.9 million for the first three quarters of the year and expects significant revenue in the fourth quarter to offset operating expenses [30][31] - The company aims to cover operating expenses through financings and anticipates a good fourth quarter [31][32] - The market value of the company's equity holdings in Pollex Bio and Buda Juice is expected to provide substantial upside for shareholders [31][32] Business Line Data and Key Metrics Changes - The company is focused on launching three to five companies per year to build a public venture portfolio, which is a shift from the historical rate of one company every 18 months [9][24] - The company has a deep pipeline of opportunities and believes that future launches will have a better probability of success than past ones [24][27] Market Data and Key Metrics Changes - The microcap market has been challenging, but the company believes that transparency and liquidity in public markets will become attractive again [28][30] - There is a growing demand for small public companies with revenue and earnings, as many are moving towards private equity routes [29][30] Company Strategy and Development Direction - The company aims to create a sustainable operational framework to support the launch of public venture companies and believes it has a unique position in the market [16][39] - The strategy includes curating and positioning companies for success in the public markets, focusing on those with significant growth potential [10][15] - The company is also exploring the potential of a spinout in the patent law sector, which could provide substantial value [34][64] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges in the microcap market but remains optimistic about future opportunities and the potential for public venture to thrive [28][30] - The company is committed to improving communication with shareholders and addressing concerns about stock performance [68][70] Other Important Information - The company has a unique model that combines operational support with equity positions in the companies it helps launch, which differentiates it from traditional underwriters and VCs [21][39] - The company is actively working on building its community to support its ventures and enhance its operational capabilities [25][26] Q&A Session Summary Question: When can shareholders expect to see a dividend? - The company prefers to wait until there is a developed market for the stock and broader ownership before considering dividends [42] Question: How will MDB handle ownership percentages during fundraising for Exazyme? - Shareholders can expect dilution as companies raise more capital, but efforts will be made to minimize this [43] Question: What is the outlook for Heartbeat regarding FDA approval? - The company is optimistic about FDA approval and believes it will facilitate future fundraising efforts [46] Question: Why is the stock trading at a low price compared to the IPO? - The poor performance of the microcap market and concerns about the company's ability to select successful ventures are contributing factors [48] Question: What makes the cost of being public more favorable for listings? - Companies that are profitable and growing in the microcap sector are trading at attractive valuations, making public listings more appealing [50][51] Question: Can you clarify the PatentVest spinout and its potential? - The spinout is expected to have substantial market value due to the disruption AI will bring to the legal sector, particularly in patent law [63][66]

Core Viewpoint - MDB Capital Holdings is making significant progress in scaling its public venture platform and aims to create a diversified portfolio of high-potential public venture opportunities [3]. Operational Highlights - The company anticipates closing two offerings shortly: a $16.8 million private placement for Paulex Bio, focused on diabetes therapeutics, and a $20 million IPO for Buda Juice, which offers UltraFresh™ cold-crafted juices [8]. - MDB Capital has expanded its pipeline of early-stage, disruptive companies that have the potential to lead in new categories [8]. - The firm is improving the efficiency of its public venture platform to better identify and prepare new category-leading companies with disruptive technologies [8]. - MDB welcomed TCA Venture Group and Keiretsu Forum MST angel group investors into its latest offerings, enhancing its investor community [8]. - The company has broadened relationships with Registered Investment Advisors (RIAs) to attract new investors seeking alternative investment strategies [8].